AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lexaria Bioscience Corp. Director's Dealing 2024

Dec 3, 2024

34983_dirs_2024-12-03_a39b27aa-6452-4984-b7ab-1387b620d313.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2024-12-02

Reporting Person: CHRISTOPHER RICHARD (Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-02	common shares	P	22828	$2.2436	Acquired	22828	Direct
2024-12-03	common shares	P	27172	$2.4722	Acquired	50000	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$3.92	2029-08-31	Common Shares (200000)	200000	Direct

Footnotes

F1: Options are vested as to 50,000 on February 28, 2025 with 6,818 being vested monthly thereafter until November 30, 2026 whereby the balance of 6,822 options will be vested on December 31, 2026